国浩律师（深圳）事务所 法律意见书 国浩律师（深圳）事务所 关于武汉回盛生物科技股份有限公司 2025年第三次临时股东大会法律意见书 致：武汉回盛生物科技股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受武汉回盛生物科技股份 有限公司（以下简称"公司"）的委托，指派彭瑶律师、季俊宏律师（以下简称 "本所律师"）出席公司2025年第三次临时股东大会（以下简称"本次股东大会" 或"本次会议"），对本次股东大会的合法性进行见证。本所律师根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法 律、法规和规范性文件以及《武汉回盛生物科技股份有限公司章程》（以下简称 "《公司章程》"）的规定，就公司本次股东大会的召集、召开程序、出席会议 人员的资格、召集人的资格、表决程序和表决结果等有关事宜出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人的资格、表决程序以及表决结果是否符合相关法律、法规、 其他规范性文件及《公司章程》的规定发表意见，不对会议审议的议案内容以及 这些议案所表述的事实或数据的真实性及准确性发表意见。 按照律师行 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-096 武汉回盛生物科技股份有限公司 关于董事会换届选举完成及聘任高级管理人员、证券事务代表 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开 2025 年第三次临时股东大会，审议通过了《关于董事会换届暨选举 第四届董事会非独立董事的议案》《关于董事会换届暨选举第四届董事会独立 董事的议案》，选举产生了第四届董事会非职工代表董事，与公司职工代表大 会选举产生的第四届董事会职工代表董事周健女士，共同组成公司第四届董事 会。同日，公司召开第四届董事会第一次会议，选举产生了第四届董事会董事 长、各专门委员会委员，聘任了公司高级管理人员及证券事务代表。现将有关 情况公告如下： 一、第四届董事会及各专门委员会的组成情况 （一）第四届董事会的组成情况 非独立董事：张卫元先生（董事长）、刘泽祥先生 独立董事：冉明东先生、汪明先生 职工代表董事：周健女士 公司第四届董事会由 5 名董事组成，其中独立董事 2 名，职工代 ...

第四届董事会第一次会议决议公告 证券代码：300871 证券简称：回盛生物 公告编号：2025-095 武汉回盛生物科技股份有限公司 （一）审议通过了《关于选举第四届董事会董事长的议案》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《公司法》《公司章程》等有关规定，公司全体董事一致同意选举张 卫元先生担任公司第四届董事会董事长，任期三年，自本次董事会审议通过之 日起至第四届董事会任期届满之日止。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披露的《关于董 事会换届选举完成及聘任高级管理人员、证券事务代表的公告》（公告编号： 1 2025-096）。 表决结果为：同意 5 票；反对 0 票；弃权 0 票。本议案获得通过。 一、董事会会议召开情况 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 16 日召开的 2025 年第三次临时股东大会选举产生的第四届董事会非职工代表 董事，以及于 2025 年 9 月 28 日召开的 2025 年第一次职工代表大会选举产生 的第四届董事会职工代表董事，共同组成第四届 ...

Group 1 - The core viewpoint of the news is that Huisheng Biological has experienced fluctuations in its stock price and trading volume, with a significant increase in stock price year-to-date, but recent declines in the short term [1] - As of October 16, Huisheng Biological's stock price was 20.92 yuan per share, with a market capitalization of 4.233 billion yuan and a trading volume of 80.2648 million yuan [1] - The company has seen a net outflow of main funds amounting to 2.2558 million yuan, with large orders showing a mixed buying and selling pattern [1] Group 2 - Huisheng Biological operates primarily in the veterinary medicine sector, with 93.56% of its revenue coming from veterinary raw materials and formulations [1] - As of June 30, the number of shareholders increased by 65.21% to 23,500, while the average number of circulating shares per person decreased by 28.44% [2] - For the first half of 2025, Huisheng Biological reported a revenue of 822 million yuan, representing a year-on-year growth of 88.45%, and a net profit attributable to shareholders of 117 million yuan, up 325.88% year-on-year [2] Group 3 - Since its A-share listing, Huisheng Biological has distributed a total of 236 million yuan in dividends, with 135 million yuan distributed over the past three years [3]

当日关注点 董秘： 尊敬的投资者，您好！近年来公司积极拓展海外市场，海外业务销售呈现良好的发展态势。目 前海外业务构成主要以原料药出口为主，制剂出海业务处于探索期。感谢您的关注！ 投资者： 董秘好，很多创业板公司预告了三季度业绩，贵司同属于创业板公司，为什么不做预告？ 董秘： 尊敬的投资者，您好！公司三季度业绩情况请您关注公司后续公告，公司三季报预约披露时间 为10月28日。感谢您的关注！ 投资者： 请问公司定向增发受理已超过3个月，是否仍未收到证监会的审批决定？ 董秘： 尊敬的投资者，您好！公司向特定对象发行股票的审核问询函已回复，相关进展情况请关注公 司后续公告。感谢您的关注！ 截至2025年10月15日收盘，回盛生物(300871)报收于21.35元，上涨1.47%，换手率2.25%，成交量4.55万 手，成交额9656.41万元。 董秘最新回复 投资者： 董秘好，在这个不出海就出局的时代，公司的产品在海外有竞争力吗？公司在出海方面是如 何布局的？谢谢 来自交易信息汇总：10月15日主力资金净流入123.84万元，显示主力对回盛生物的短期关注度提 升。 交易信息汇总资金流向 10月15日主力资金净流入1 ...

（文章来源：每日经济新闻） 回盛生物（300871.SZ）10月15日在投资者互动平台表示，尊敬的投资者，您好！近年来公司积极拓展 海外市场，海外业务销售呈现良好的发展态势。目前海外业务构成主要以原料药出口为主，制剂出海业 务处于探索期。 每经AI快讯，有投资者在投资者互动平台提问：董秘好，在这个不出海就出局的时代，公司的产品在 海外有竞争力吗？公司在出海方面是如何布局的？ ...

Core Viewpoint - The animal health sector experienced a decline of 0.68% on October 14, with Xianfeng Holdings leading the drop. The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1]. Stock Performance Summary - Zhongmu Co., Ltd. (600195) closed at 7.35, up 1.66% with a trading volume of 120,000 shares and a transaction value of 87.91 million yuan [1]. - Yongshun Biological (920729) closed at 9.31, up 0.54% with a trading volume of 13,800 shares and a transaction value of 12.82 million yuan [1]. - Biological Co. (600201) closed at 10.60, up 0.28% with a trading volume of 624,200 shares and a transaction value of 672 million yuan [1]. - Other notable stocks include Ruip Bio (300119) down 0.45% and Jinhai Bio (002688) down 0.98% [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 8.12 million yuan from institutional investors, while retail investors had a net inflow of 4.61 million yuan [2][3]. - Major stocks like Biological Co. (600201) experienced a net inflow of 62.91 million yuan from institutional investors, while Xianfeng Holdings (002141) saw a net outflow of 9.04 million yuan [3].

Core Insights - The animal health sector experienced a rise of 1.98% on October 10, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 10.16, up 4.42% with a trading volume of 808,300 shares and a transaction value of 815 million [1] - Other notable performers included: - Houbang Holdings (002141) at 3.85, up 3.77% [1] - Ruipu Biological (300119) at 21.87, up 3.16% [1] - Dayu Biological (920970) at 66.6, up 2.62% [1] - Huisheng Biological (300871) at 21.33, up 2.06% [1] Capital Flow - The animal health sector saw a net inflow of 111 million from institutional investors, while retail investors experienced a net outflow of 96.24 million [2] - The capital flow for key stocks included: - Bio-Pharmaceuticals (600201) with a net inflow of 73.87 million from institutional investors [3] - Huisheng Biological (300871) with a net inflow of 17.64 million from institutional investors [3] - Houbang Holdings (002141) with a net inflow of 16.38 million from institutional investors [3]

Core Insights - The animal health sector experienced a slight increase of 0.01% on October 9, with the leading stock being Driveline [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Driveline (920275) closed at 9.57, up 1.38%, with a trading volume of 17,600 and a turnover of 11.63 million [1] - Jinhai Biological (002688) closed at 6.77, up 1.20%, with a trading volume of 183,400 and a turnover of 123 million [1] - Biological Shares (600201) closed at 9.73, up 0.93%, with a trading volume of 470,500 [1] - Huisheng Biological (300871) closed at 20.90, up 0.87%, with a trading volume of 41,600 [1] - Other notable stocks include Plai Ke (603566) at 13.82, up 0.58%, and Haili Biological (603718) at 6.81, up 0.15% [1] Capital Flow - The animal health sector saw a net outflow of 53.09 million from institutional investors, while retail investors had a net inflow of 28.12 million [2] - The total net inflow from speculative funds was 24.97 million [2] Individual Stock Capital Flow - Ruipu Biological (300119) had a net inflow of 7.31 million from institutional investors, while it experienced a net outflow of 9.14 million from retail investors [3] - Plai Ke (603566) saw a net inflow of 2.41 million from institutional investors but a net outflow of 6.28 million from retail investors [3] - Other stocks like *ST Green Kang (002868) and Jinhai Biological (002688) experienced significant net outflows from institutional investors [3]

Group 1 - The core point of the article is the announcement by Huisheng Biological regarding the composition of its fourth board of directors, which will consist of 5 members, including 2 non-independent directors, 2 independent directors, and 1 employee representative director [1] - The board has nominated Zhang Weiyuan and Liu Zexiang as candidates for non-independent directors, while Ran Mingdong and Wang Ming are nominated as candidates for independent directors [1]